Rapid re-definition of a major R&D transformation program to underpin Scientific Innovation, one of the five core strategic growth drivers for a $5bn global consumer healthcare business



Aprio


  • Designed the program of programs to deliver a global Consumer Healthcare 3-year business strategy. This included execution of 5 core pillars of the ‘Winning Formula’ strategy, one of which was Scientific Innovation
  • The global R&D team had been tasked with defining and implementing a transformation program to underpin delivery of this strategic pillar, but had not made the progress the CEO had been looking for. A Global PMI Partners Partner was engaged to turn it around.
  • Working with the R&D leadership team in the US and UK, within 4 weeks, the R&D transformation program had been clearly defined into 11 core workstreams, including: Consumer First, Metrics, Open Innovation, Speed to Market, Value Engineering, Global Resourcing, Regulatory Speed to Approval, Collaboration with Pharma, Scientific Excellence Capability, IT and Comms
  • Within 6 weeks, the global R&D leadership team presented their new plan to the CEO, achieving approval in all product areas: nutrition, wellness, oral health and skin health, the science and innovation behind many of GSK’s global brands, such as Sensodyne


Sector/s
Healthcare
Pharmaceuticals

Services Delivered
M&A Capabilities

Countries Involved
United States
United Kingdom
India

China
Europe
RoW


We use cookies to give you the best experience with our website. By continuing to browse this site, you are agreeing to our use of cookies. For more on how we use information collected, please see our Privacy Policy.